Suchen
Ionis Pharmaceuticals Inc
IONSZur Watchlist hinzufügen
42.860USD
-0.070-0.16%
Trading geöffnet 10/26, 14:38（ET）
7.12BMarktkapitalisierung
VerlustKGV TTM
Über Ionis Pharmaceuticals Inc Unternehmen
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc Profil
BörsenkürzelIONS
Name des UnternehmensIonis Pharmaceuticals Inc
IPO-datumMay 17, 1991
CEOMonia (Brett P)
Anzahl der mitarbeiter1069
WertpapierartOrdinary Share
GeschäftsjahresendeMay 17
Addresse2855 Gazelle Court
StadtCARLSBAD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92010
Telefon17609319200
Websitehttps://www.ionis.com/
BörsenkürzelIONS
IPO-datumMay 17, 1991
CEOMonia (Brett P)
Führungskräfte von Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.76K
+0.04%
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.76K
+0.04%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
161.30K
+3.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
161.30K
+3.24%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President - Corporate and Development Operations
Executive Vice President - Corporate and Development Operations
67.56K
+0.09%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President - Corporate and Development Operations
Executive Vice President - Corporate and Development Operations
67.56K
+0.09%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
--
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.76K
+0.04%
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.76K
+0.04%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
161.30K
+3.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
161.30K
+3.24%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc sind: Dr. Brett P. Monia, Ph.D.
Wie viele Institutionen halten Anteile an Ionis Pharmaceuticals Inc (IONS)?
Mit Stand vom 2026Q1 halten 942 Institutionen Anteile an Ionis Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 197.51M, was 119.51% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 12089606.00 gestiegen.
Was ist die größte Einnahmequelle von Ionis Pharmaceuticals Inc?
Am 2026Q1 erzielte das Geschäft mit R&D revenue under collaborative agreements für Ionis Pharmaceuticals Inc den höchsten Umsatz in Höhe von 364.56M, was 49.99% des Gesamtumsatzes entspricht.